Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: A review of the literature

Neurocritical Care

Volumn 12, Issue 3, 2010, Pages 403-413

  Bershad, Eric M ^a   Suarez, Jose I ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Coagulopathy; Intracerebral hemorrhage; Intracranial bleeding; Intracranial hemorrhage; Oral anticoagulation; Prothrombin complex concentrates; Vitamin K antagonists; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; BERIPLEX P N; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; COFACT; D DIMER; FATTY ACID BINDING PROTEIN; FIBRINOGEN; FRESH FROZEN PLASMA; HEPARIN; OCTAPLEX; PLACEBO; PPSB HT NICHIYAKU; PROPLEX T; PROTEIN C; PROTEIN S; PROTHROMBIN; PROTHROMBIN COMPLEX; PROTHROMBINEX HT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ARTERIAL THROMBOEMBOLISM; ARTERY OCCLUSION; BLEEDING; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG OVERDOSE; DRUG SAFETY; HEART INFARCTION; HEMODYNAMICS; HEMOPHILIA B; HUMAN; INFECTION RISK; INFUSION RATE; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SEROCONVERSION; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOGENICITY; TRANSFUSION RELATED ACUTE LUNG INJURY; VEIN OCCLUSION; VENOUS THROMBOEMBOLISM; VIRUS TRANSMISSION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL HEMORRHAGES; PLASMA; PLATELET COUNT; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBIN TIME; THROMBOEMBOLISM; WARFARIN;

EID: 77955094322     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-009-9310-0     Document Type: Review

References (75)

1. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444-1451
2. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26(8):1471-1477
3. Butler AC, Tait RC. Management of oral anticoagulant-induced intracranial haemorrhage. Blood Rev. 1998;12(1):35-44.
4. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897-902.
5. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349(18):1703- 1712
6. Lavoie A, Ratte S, Clas D, Demers J, Moore L, Martin M, et al. Preinjury warfarin use among elderly patients with closed head injuries in a trauma center. J Trauma. 2004;56(4):802-807
7. Mina AA, Bair HA, Howells GA, Bendick PJ. Complications of preinjury warfarin use in the trauma patient. J Trauma. 2003 ;54(5):842-847
8. Neau JP, Couderq C, Ingrand P, Blanchon P, Gil R. Intracranial hemorrhage and oral anticoagulant treatment. Cerebrovasc Dis. 2001;11(3):195-200.
9. Franke CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990;21(5):726-730
10. Radberg JA, Olsson JE, Radberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke. 1991;22(5):571-576
11. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2006;37(1):256-262
12. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059-1064
13. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004; 164(8):880-884
14. Bershad EM, Farhadi S, Suri MF, Feen ES, Hernandez OH, Selman WR, et al. Coagulopathy and inhospital deaths in patients with acute subdural hematoma. J Neurosurg. 2008;109(4):664-669
15. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77(3):477-480
16. Baglin T. Management of warfarin (coumarin) overdose. Blood Rev. 1998;12(2):91-98
17. Taberner DA, Thomson JM, Poller L. Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. Br Med J. 1976;2(6027):83-85
18. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83(2): 137-143
19. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edition. Chest. 2008;133(6 Suppl):160S-98S.
20. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999, 83(2):286-288 (A286-287).
21. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163(20): 2469-2473
22. Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol. 2005;42(3):365-370
23. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): 3rd edition-2005 update. Br J Haematol. 2006;132(3):277-285
24. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358(20): 2127-2137
25. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352(8):777-785
26. rFVIIa in ICH in patients treated with anticoagulants or antiplatelets. www.clinicaltrials.gov.
27. Appelboam R, Thomas EO. The headache over warfarin in British neurosurgical intensive care units: a national survey of current practice. Intensive Care Med. 2007;33(11):1946-1953
28. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181(9):492-497
29. Tullis JL, Melin M. Management of Christmas disease and Stuart-Prower deficiency with a prothrombin-complex concentrate (factors II, VII, IX, X). Bibl Haematol. 1968;29:1134-1139
30. Sandler SG, Rath CE, Ruder A. Prothrombin complex concentrates in acquired hypoprothrombinemia. Ann Intern Med. 1973;79(4):485-491
31. Josic D, Hoffer L, Buchacher A, Schwinn H, Frenzel W, Biesert L, et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res. 2000;100(5):433-441
32. Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res. 1999;95(4 Suppl 1):S7-12.
33. McQuillan AM, Eikelboom JW, Hankey GJ, Baker R, Thom J, Staton J, et al. Protein Z in ischemic stroke and its etiologic subtypes. Stroke. 2003;34(10):2415-2419 (Pubitemid 37221953)
34. Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004;113(6):371-378
35. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol. 2001;115(4):998-1001.
36. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98(4):90-97
37. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery. 1999;45(5):1113-8. discussion 1118-1119.
38. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgicalemergencies. Br J Neurosurg. 2000;14(5):458-461
39. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992; 23(7):972-977
40. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4(5):967-970
41. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6(4):622-631
42. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;116(3):619-624
43. Vigue B, Ract C, Tremey B, Engrand N, Leblanc PE, Decaux A, et al. Ultra-rapid management of oral anticoagulant therapyrelated surgical intracranial hemorrhage. Intensive Care Med. 2007;33(4):721-725
44. Yasaka M, Oomura M, Ikeno K, Naritomi H, Minematsu K. Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Hematol. 2003;82(2):121-123
45. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006; 118(3):313-320
46. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12(4):R105.
47. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res. 2005;115(6):455-459
48. Hellstern P, Halbmayer WM, Kohler M, Seitz R, Muller-Berghaus G. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res. 1999;95(4 Suppl 1):S3-6.
49. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev. 2007;21(1):37-48.
50. Pindur G, Morsdorf S. The use of prothrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation. Thromb Res. 1999;95(4 Suppl 1):S57-61.
51. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol. 2001;114(2): 271-280
52. Crawford JH, Augustson BM. Prothrombinex use for the reversal of warfarin: is fresh frozen plasma needed? Med J Aust. 2006; 184(7):365-366
53. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49(6):1171-1177
54. Blatt PM, Lundblad RL, Kingdon HS, McLean G, Roberts HR. Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med. 1974;81(6):766-770
55. Schimpf K, Zeltsch C, Zeltsch P. Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A. Lancet. 1982;2(8306):1043.
56. Hampton KK, Preston FE, Lowe GD, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol. 1993;84(2):279-284
57. Aledort LM. Factor IX and thrombosis. Scand J Haematol Suppl. 1977;30:40-42
58. Kohler M, Heiden M, Harbauer G, Miyashita C, Morsdorf S, Braun B, et al. Comparison of different prothrombin complex concentrates-in vitro and in vivo studies. Thromb Res. 1990; 60(1):63-70.
59. Hellstern P, Beeck H, Fellhauer A, Fischer A, Faller-Stockl B. Factor VII and activated-factor-VII content of prothrombin complex concentrates. The PCC Study Group. Vox Sang. 1997;73(3): 155-161
60. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95(4 Suppl 1):S13-7.
61. WhiteGCII, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood. 1977;49(2): 159-170
62. Gray E, Tubbs J, Thomas S, Oates A, Boisclair M, Kemball-Cook G, et al. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost. 1995;73(4):675-679
63. Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits. Blood. 1982;59(2):401-407
64. Lusher JM. Prediction and management of adverse events associated with the use of factor IX complex concentrates. Semin Hematol. 1993;30(2 Suppl 1):36-40.
65. Roddie PH, Stirling C, Mayne EE, Ludlam CA. Thrombosis and disseminated intravascular coagulation following treatment with the prothrombin complex concentrate, DEFIX. Thromb Haemost. 1999;81(4):667.
66. Pindur G, Morsdorf S, Schenk JF, Krischek B, Heinrich W, Wenzel E. The overdosed patient and bleedings with oral anticoagulation. Semin Thromb Hemost. 1999;25(1):85-88
67. Preiss DU, Eberspacher B, Abdullah D, Rosner I. Safety of vapour heated prothrombin complex concentrate (PCC) Prothromplex S-TIM 4. Thromb Res. 1991;63(6):651-659
68. Morfini M, Longo G, Berntorp E, Cinotti S, Filimberti E, Messori A, et al. Pharmacokinetics, thrombogenicity and safety of a doubletreated prothrombin complex concentrate. Thromb Res. 1993; 71(3):175-184
69. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79(3):826-831
70. Seitz R, Dodt J. Virus safety of prothrombin complex concentrates and factor IX concentrates. Thromb Res. 1999;95(4 Suppl 1):S19-23.
71. Taketomi T, Szlam F, Levy JH, Tanaka KA. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. Blood Coagul Fibrinolysis. 2008;19(1):106-108
72. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res. 2007;119(5):643-651
73. Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37(6):1465-1470
74. Kalina M, Tinkoff G, Gbadebo A, Veneri P, Fulda G. A protocol for the rapid normalization of INR in trauma patients with intracranial hemorrhage on prescribed warfarin therapy. Am Surg. 2008;74(9):858-861
75. Nitu IC, Perry DJ, Lee CA. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clin Lab Haematol. 1998;20(6):363-7. 414-420